Abstract 257P
Background
GTN comprises a unique group of tumours that originate from trophoblastic tissues which includes Invasive mole, choriocarcinoma and Placental site trophoblastic tumour and with proper treatment low-risk GTN is 100% curable. This study was carried out to evaluate the management outcome of low risk GTN patients to the accepted 1st line treatment regimens followed in the hospital.
Methods
205 patients of gestational trophoblastic disease who were registered at the institute between January 2016 and December 2018 were analysed retrospectively. Risk stratification & Staging was done according to Revised FIGO 2002 staging system. All low risk patients were included the study.
Results
Out of 205 ,46 (22%) patients were diagnosed with GTN (low-risk 43/205(21.5%). 37(86.04%) patients received single agent Methotrexate (weekly) while 4 (9.3%) patients received Actinomycin D (bi-weekly) as first line. Methotrexate/LV was given for 2 patients. 67.5%(n = 25/37) achieved Complete Response (CR) on Methotrexate while 32.4%(n = 12/37) went on to get second line.62.5%(n = 10/16) received ACT-D in second line while multi-drug chemotherapy was given to 5 patients (31%,5/16). CR was achieved in 84.62%(n = 11) in 2nd line while 1 patient went on to get 3rd line chemotherapy. Anemia was the most common complication associated with the disease and treatment.
Conclusions
Low- risk GTN is a highly chemo-sensitive tumor and 100% curable. methotrexate as single agent produced 67.5% of complete remission. Single agent methotrexate is still one of the preferred first-line regimes for low risk GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
The author has declared no conflicts of interest.
Resources from the same session
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract